Prompted by a recent study on the effects of smoking on colorectal cancer survival, Dr David Kerr reports that he has increased his efforts to get his patients to stop smoking.

Dr John Marshall discusses how the current requirements for declaring conflict of interest are complicating cancer research and possibly barring the best minds from working together.

Dr Maurie Markman discusses a recent CDC survey revealing that 1 in 10 US adult women were not screened for cervical cancer during a recent 5-year period.

Will US and European guidelines follow the UK's lead and incorporate value metrics in their recommendations? Dr. John Marshall, reporting on a discussion at GICS, says it's only a matter of time.

Drs Kathy Miller, Clifford Hudis, and George Sledge discuss the pros and cons of testing novel breast cancer treatments in the neoadjuvant setting, with special reference to pertuzumab.

Drs Richard Zellar and Kathy Miller, at SABCS 2014, discuss locoregional breast cancer therapies, including partial breast irradiation, surgery vs radiation of sentinel nodes, and DCIS scoring.

Dr Brandon Smaglo reports on 2 studies from 2015 GCIS, one showing benefit from pembrolizumab in gastric cancer, another suggesting that less palliative therapy may be warranted in esophageal cancer.

Dr Mark Kris discusses the switch from first- to second-line therapy for EGFR mutant lung cancers in light of two studies presented at the most recent ESMO meeting.

If opportunities to screen for cervical cancer or vaccinate for HPV were not missed, cervical cancer rates would plummet.

Dr John Marshall asks tough questions of experts at the 2014 Ruesch Symposium about whether information gained from molecular testing can tailor therapy and lower costs.